AFM and metabolic dysfunction-associated steatotic liver disease: Other studies have shown that urinary afamin predicts development and progression of DKD in patients with T2D and that afamin is upregulated in serum samples from patients with nonalcoholic fatty liver disease, suggesting that early identification of patients with elevated afamin levels may identify patients at high risk of IR-related diseases (24, 25).